Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 19, 2026

Stock market today: Dow, S&P 500, Nasdaq turn lower with oil prices, Walmart, rate-cut bets in focus

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq turn lower with oil prices, Walmart, rate-cut bets in focus US stocks turned firmly into the red on Thursday as US-Iran fears spurred a continued rally in oil, with Walmart (WMT) earnings and Federal Reserve rate-cut odds in focus…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Talks between Tehran and Washington had reached a potential framework for a deal on Iran's nuclear program

    80% confidence
  • DoorDash expects marketplace GOV to be in range of $31.0 billion to $31.8 billion for Q1 2026

    80% confidence
  • Trump administration is edging toward military conflict with Iran

    80% confidence
  • US has largest air power armament in Middle East since invasion of Iraq in 2003

    80% confidence
  • SK Hynix set price of HBM4 for Nvidia in mid-$500 range in August but may move to match Samsung's higher number

    80% confidence
  • DoorDash expects adjusted EBITDA to be in range of $675 million to $775 million for Q1 2026

    80% confidence
  • Walmart faces headwinds including tariffs, geopolitical conditions, and inflation in year ahead

    80% confidence
  • Samsung is negotiating price for HBM4 at around $700 per unit, up to 30% higher than previous generation

    80% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · interest rate target range low3.5 percent
Board of Governors of the Federal Reserve System · interest rate target range high3.75 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Stock market today: Dow, S&P 500, Nasdaq turn lower with oil prices, Walmart, rate-cut bets in focus — Source | Via News | ViaNews Market